PHX
PHAXIAM Therapeutics S A ADR
Stock
Stock
ISIN: US29604W2070
Ticker: PHXM
US29604W2070
PHXM
Price
Price
CHART BY
Frequently asked questions
What is the Earnings Per Share (EPS) for PHAXIAM Therapeutics S A ADR?
PHAXIAM Therapeutics S A ADR's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -3.75. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for PHAXIAM Therapeutics S A ADR's stock?
Currently, 1 analysts cover PHAXIAM Therapeutics S A ADR's stock, with a consensus target price of 5.111. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for PHAXIAM Therapeutics S A ADR?
PHAXIAM Therapeutics S A ADR's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -23.41M. EBITDA measures the company's overall financial performance.
What is the free cash flow of PHAXIAM Therapeutics S A ADR?
PHAXIAM Therapeutics S A ADR has a free cash flow of -23.25M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does PHAXIAM Therapeutics S A ADR have, and what sector and industry does it belong to?
PHAXIAM Therapeutics S A ADR employs approximately 68 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of PHAXIAM Therapeutics S A ADR's shares?
The free float of PHAXIAM Therapeutics S A ADR is 9.41M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- EPS (TTM)
- -3.75
- Free Float
- 9.41M
- EBITDA (TTM)
- -23.41M
- Free Cashflow (TTM)
- -23.25M
Analyst Ratings
The price target is 5.111 and the stock is covered by 1 analysts.
Buy
1
Hold
0
Sell
0
Information
PHAXIAM Therapeutics SA operates as a biopharmaceutical company. It engages in the development of treatments for resistant bacterial infections. The firm develops antibacterial treatments based on the use of bacteriophage viruses, or phages, to combat bacterial infections in humans, particularly those resistant to antibiotics. The company was founded in 2004 and is headquartered in Lyon, France.
- Employees
- 68
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- US29604W2070
- Primary Ticker
- PHXM
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet